flumazenil has been researched along with Cirrhosis, Liver in 28 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the double blind randomized, placebo controlled study, 54 patients with hepatic encephalopathy grade III-IV were randomly assigned to receive either flumazenil 2 mg iv (group A) or placebo (group B); conventional treatment with branched-chain amino acid, saline, glucose, and lactulose was administered in both groups." | 9.09 | Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. ( Balzano, A; Laccetti, M; Lioniello, M; Manes, G; Rabitti, PG; Uomo, G, 2000) |
| "4-1 mg flumazenil results in a modest but rapid improvement in the EEG grading of hepatic encephalopathy and to a moderate but delayed improvement in the clinical grade of hepatic encephalopathy." | 9.08 | Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. ( Benhamou, Y; Cadranel, JF; el Younsi, M; Opolon, P; Pidoux, B; Valla, D; Zylberberg, P, 1995) |
| "To evaluate the beneficial and harmful effects of flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy." | 8.95 | Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017) |
| "To evaluate the beneficial and harmful effects of flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy." | 8.95 | Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017) |
| "An overview of randomized controlled trials comparing flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis was performed." | 8.81 | Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. ( Bernard, B; Cadranel, JF; Di Martino, V; Goulenok, C; Opolon, P; Poynard, T; Thabut, D, 2002) |
| " We evaluated the visual EP, brain stem auditory EP, and somatosensory EP (SSEP) and the effect of benzodiazepine receptor antagonist flumazenil in patients with liver cirrhosis." | 7.69 | Evoked potentials and the effect of flumazenil in patients with liver cirrhosis. ( Arik, Z; Kahraman, H; Kesim, G; Onar, M; Ozyilkan, E, 1997) |
| "Treatment of chronic hepatic encephalopathy is difficult." | 5.29 | [Chronic hepatic encephalopathy treated by long-term intravenous administration of flumazenil in ambulatory care]. ( Frappa, B; Paolini, O; Péroux, JL; Rampal, P; Tran, A, 1996) |
| "Flumazenil was not found to induce significant changes in the clinical status or in maps of the cerebral activity of patients with chronic encephalopathy." | 5.28 | [Evaluation of the therapeutic effect of flumazenil in hepatic encephalopathy using cerebral cartography]. ( Bello Mimbrera, G; de la Torre Fernández, JM; de la Torre Gutiérrez, S; García de León, M; Montero Vázquez, J; Torres Salcines, J, 1989) |
| " In the double blind randomized, placebo controlled study, 54 patients with hepatic encephalopathy grade III-IV were randomly assigned to receive either flumazenil 2 mg iv (group A) or placebo (group B); conventional treatment with branched-chain amino acid, saline, glucose, and lactulose was administered in both groups." | 5.09 | Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study. ( Balzano, A; Laccetti, M; Lioniello, M; Manes, G; Rabitti, PG; Uomo, G, 2000) |
| "4-1 mg flumazenil results in a modest but rapid improvement in the EEG grading of hepatic encephalopathy and to a moderate but delayed improvement in the clinical grade of hepatic encephalopathy." | 5.08 | Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. ( Benhamou, Y; Cadranel, JF; el Younsi, M; Opolon, P; Pidoux, B; Valla, D; Zylberberg, P, 1995) |
| "To evaluate the beneficial and harmful effects of flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy." | 4.95 | Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017) |
| "To evaluate the beneficial and harmful effects of flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy." | 4.95 | Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy. ( Andersen, ML; Gluud, LL; Goh, ET; Morgan, MY, 2017) |
| "An overview of randomized controlled trials comparing flumazenil and placebo in hepatic encephalopathy in patients with cirrhosis was performed." | 4.81 | Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. ( Bernard, B; Cadranel, JF; Di Martino, V; Goulenok, C; Opolon, P; Poynard, T; Thabut, D, 2002) |
| " We evaluated the visual EP, brain stem auditory EP, and somatosensory EP (SSEP) and the effect of benzodiazepine receptor antagonist flumazenil in patients with liver cirrhosis." | 3.69 | Evoked potentials and the effect of flumazenil in patients with liver cirrhosis. ( Arik, Z; Kahraman, H; Kesim, G; Onar, M; Ozyilkan, E, 1997) |
| "Seventy-seven cirrhotic patients in hepatic coma were evaluated." | 2.67 | Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial. ( Butterworth, RF; D'Amour, M; Gagnon, S; Giguère, JF; Lavoie, J; Perney, P; Pomier-Layrargues, G; Wells, J, 1994) |
| " The oral route is optimized by dosing every hour until stool evacuation appears." | 1.31 | Hepatic Encephalopathy. ( Blei, AT; Córdoba, J, 2001) |
| "Treatment of chronic hepatic encephalopathy is difficult." | 1.29 | [Chronic hepatic encephalopathy treated by long-term intravenous administration of flumazenil in ambulatory care]. ( Frappa, B; Paolini, O; Péroux, JL; Rampal, P; Tran, A, 1996) |
| "Recently it was suggested that hepatic encephalopathy (HE) is mediated by an increased GABA-ergic tone." | 1.28 | Benzodiazepine antagonist in the treatment of human hepatic encephalopathy. ( Ferenci, P; Grimm, G, 1990) |
| "Flumazenil was not found to induce significant changes in the clinical status or in maps of the cerebral activity of patients with chronic encephalopathy." | 1.28 | [Evaluation of the therapeutic effect of flumazenil in hepatic encephalopathy using cerebral cartography]. ( Bello Mimbrera, G; de la Torre Fernández, JM; de la Torre Gutiérrez, S; García de León, M; Montero Vázquez, J; Torres Salcines, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 16 (57.14) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 4 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goh, ET | 2 |
| Andersen, ML | 2 |
| Morgan, MY | 2 |
| Gluud, LL | 2 |
| Kim, SI | 1 |
| Jin, YJ | 1 |
| Lee, SH | 1 |
| Lee, JW | 1 |
| Lee, DH | 1 |
| Lee, D | 1 |
| Butterworth, RF | 3 |
| Romero-Gómez, M | 1 |
| Kapczinski, F | 3 |
| Sherman, D | 1 |
| Williams, R | 1 |
| Lader, M | 2 |
| Curran, V | 1 |
| Cadranel, JF | 2 |
| el Younsi, M | 1 |
| Pidoux, B | 1 |
| Zylberberg, P | 1 |
| Benhamou, Y | 1 |
| Valla, D | 1 |
| Opolon, P | 2 |
| Perney, P | 3 |
| Pomier-Layrargues, G | 2 |
| Sterling, RK | 1 |
| Shiffman, ML | 1 |
| Schubert, ML | 1 |
| Giguère, JF | 1 |
| Lavoie, J | 2 |
| Gagnon, S | 1 |
| D'Amour, M | 1 |
| Wells, J | 1 |
| Péroux, JL | 1 |
| Paolini, O | 1 |
| Tran, A | 1 |
| Frappa, B | 1 |
| Rampal, P | 1 |
| Ozyilkan, E | 1 |
| Kahraman, H | 1 |
| Onar, M | 1 |
| Kesim, G | 1 |
| Arik, Z | 1 |
| Amodio, P | 1 |
| Marchetti, P | 1 |
| Del Piccolo, F | 1 |
| Beghi, A | 1 |
| Comacchio, F | 1 |
| Carraro, P | 1 |
| Campo, G | 1 |
| Baruzzo, L | 1 |
| Marchiori, C | 1 |
| Gatta, A | 1 |
| Barbaro, G | 2 |
| Di Lorenzo, G | 2 |
| Soldini, M | 2 |
| Giancaspro, G | 1 |
| Bellomo, G | 2 |
| Belloni, G | 2 |
| Grisorio, B | 2 |
| Annese, M | 2 |
| Bacca, D | 2 |
| Francavilla, R | 1 |
| Barbarini, G | 2 |
| Mousseau, DD | 1 |
| Fabbro-Peray, P | 1 |
| Blanc, F | 1 |
| Layrargues, GP | 1 |
| Marziali, M | 1 |
| Amaral, OB | 1 |
| Quevedo, J | 2 |
| Walz, R | 1 |
| Curran, HV | 1 |
| Fleminger, S | 1 |
| Toone, B | 1 |
| Cluckie, A | 1 |
| Giger-Mateeva, VI | 2 |
| Reits, D | 2 |
| Liberov, B | 2 |
| Jones, EA | 2 |
| Spekreijse, H | 1 |
| Blei, AT | 2 |
| Córdoba, J | 1 |
| Laccetti, M | 1 |
| Manes, G | 1 |
| Uomo, G | 1 |
| Lioniello, M | 1 |
| Rabitti, PG | 1 |
| Balzano, A | 1 |
| Riemslag, FC | 1 |
| Spekrijse, H | 1 |
| Koczorek, M | 1 |
| Goulenok, C | 1 |
| Bernard, B | 1 |
| Thabut, D | 1 |
| Di Martino, V | 1 |
| Poynard, T | 1 |
| Ferenci, P | 1 |
| Grimm, G | 1 |
| Bello Mimbrera, G | 1 |
| García de León, M | 1 |
| de la Torre Gutiérrez, S | 1 |
| Montero Vázquez, J | 1 |
| Torres Salcines, J | 1 |
| de la Torre Fernández, JM | 1 |
| Murcia, J | 1 |
| Portilla, J | 1 |
| Bedia, M | 1 |
| Palazón, JM | 1 |
| Sánchez-Payá, J | 1 |
| Saiz de la Hoya, P | 1 |
| Payá, A | 1 |
| Boix, V | 1 |
| Merino, E | 1 |
| Reus, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chinese Chronic Liver Failure Consortium Acute-on-Chronic Liver Disease and Failure Study --a Prospective Multi-center Study in China, the Largest Hepatitis B Virus High-endemic Region.[NCT02457637] | 2,600 participants (Actual) | Observational | 2015-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
be collected and reported at 28 or last visit before discharge (NCT02457637)
Timeframe: Up to 28 days
| Intervention | mg/dL (Median) |
|---|---|
| Acute-on-Chronic Liver Disease | 9.3 |
The appearance and number of organ failure（including liver, coagulation, renal, circulation, brain, respiratory system） will be evaluated and reported at 1, 4, 7, 14, 21 and 28 days (or last visit)during patients' hospitalization. (NCT02457637)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Acute-on-Chronic Liver Disease | 261 |
Mortality will be respectively calculated together with the liver transplantation rate (as the rate of ''incidence'')and independently (as the ''liver transplantation free mortality'') respectively. (NCT02457637)
Timeframe: up to 180 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 180-day mortality rate | 180-day liver transplantation rate | 180-day liver transplantation free mortality' | |
| Acute-on-Chronic Liver Disease Inpatients | 403 | 177 | 403 |
liver-transplantation free mortality refers to number of participants who died in the absence of receiving a liver transplant divided by number of participants without liver transplant. (NCT02457637)
Timeframe: up to 28 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 28-day Mortality | 28-day Liver Transplantation Rate at 28 days | 28-day liver transplantation free mortality | |
| Acute-on-Chronic Liver Disease | 74 | 124 | 74 |
liver-transplantation free mortality refers to number of participants who died in the absence of receiving a liver transplant divided by number of participants without liver transplant. (NCT02457637)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 90-day mortality rate | 90-day liver transplantation rate | 90-day liver transplantation free mortality | |
| Acute-on-Chronic Liver Disease Inpatients | 333 | 171 | 333 |
7 reviews available for flumazenil and Cirrhosis, Liver
| Article | Year |
|---|---|
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Topics: Acute Disease; Antidotes; Cause of Death; Chronic Disease; Flumazenil; GABA Modulators; GABA-A Recep | 2017 |
Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Topics: Cause of Death; Flumazenil; GABA Modulators; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Placeb | 2017 |
Pathophysiology of hepatic encephalopathy: studies in autopsied brain tissue from hepatic coma patients.
Topics: Amino Acids; Animals; Astrocytes; Biogenic Amines; Brain; Brain Chemistry; Catecholamines; Flumazeni | 1990 |
Pharmacotherapy of hepatic encephalopathy in cirrhosis.
Topics: Ammonia; Anti-Bacterial Agents; Fluid Therapy; Flumazenil; Hepatic Encephalopathy; Humans; Intestina | 2010 |
[Hepatic encephalopathy. Physiopathology and treatment].
Topics: Amino Acids; Anti-Bacterial Agents; Drug Therapy, Combination; Flumazenil; Hepatic Encephalopathy; H | 1994 |
Brain edema and portal-systemic encephalopathy.
Topics: Brain; Brain Edema; Flumazenil; Glutamine; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosi | 2000 |
Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis.
Topics: Coma; Double-Blind Method; Electroencephalography; Female; Flumazenil; Hepatic Encephalopathy; Human | 2002 |
9 trials available for flumazenil and Cirrhosis, Liver
| Article | Year |
|---|---|
Differential effects of flumazenil in alcoholic and nonalcoholic cirrhotic patients.
Topics: Adult; Anxiety; Female; Flumazenil; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Funct | 1995 |
Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study.
Topics: Adult; Aged; Double-Blind Method; Female; Flumazenil; Hepatic Encephalopathy; Humans; Infusions, Par | 1995 |
Flumazenil in cirrhotic patients in hepatic coma: a randomized double-blind placebo-controlled crossover trial.
Topics: Adolescent; Adult; Aged; Benzodiazepines; Double-Blind Method; Female; Flumazenil; GABA-A Receptor A | 1994 |
The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study.
Topics: Cognition; Cognition Disorders; Double-Blind Method; Evoked Potentials, Auditory, Brain Stem; Female | 1997 |
Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study.
Topics: Adult; Aged; Benzodiazepines; Cross-Over Studies; Double-Blind Method; Female; Flumazenil; GABA Modu | 1998 |
Flumazenil for hepatic coma in patients with liver cirrhosis: an Italian multicentre double-blind, placebo-controlled, crossover study.
Topics: Adult; Anti-Anxiety Agents; Antidotes; Cross-Over Studies; Double-Blind Method; Electroencephalograp | 1998 |
Brain uptake of iomazenil in cirrhotic patients: a single photon emission tomography study.
Topics: Adult; Brain; Female; Flumazenil; Humans; Iodine Radioisotopes; Liver Cirrhosis; Liver Function Test | 1999 |
Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study.
Topics: Coma; Double-Blind Method; Female; Flumazenil; GABA Modulators; Hemorrhage; Hepatic Encephalopathy; | 2000 |
Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil.
Topics: Adult; Arousal; Double-Blind Method; Electroencephalography; Event-Related Potentials, P300; Evoked | 2001 |
12 other studies available for flumazenil and Cirrhosis, Liver
| Article | Year |
|---|---|
Conscious Sedation Using Midazolam and Sequential Flumazenil in Cirrhotic Patients for Prophylactic Endoscopic Variceal Ligation.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Conscious Sedation; Esophageal and Gastric Varices; Esoph | 2015 |
Flumazenil for hepatic coma: the elusive wake-up call?
Topics: Cross-Over Studies; Double-Blind Method; Flumazenil; Hepatic Encephalopathy; Humans; Liver Cirrhosis | 1994 |
[Chronic hepatic encephalopathy treated by long-term intravenous administration of flumazenil in ambulatory care].
Topics: Ambulatory Care; Chronic Disease; Esophageal and Gastric Varices; Flumazenil; GABA Modulators; Hepat | 1996 |
Evoked potentials and the effect of flumazenil in patients with liver cirrhosis.
Topics: Adult; Aged; Case-Control Studies; Evoked Potentials, Auditory, Brain Stem; Evoked Potentials, Somat | 1997 |
Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake.
Topics: Animals; Benzodiazepines; Binding, Competitive; Cell Fractionation; Cerebellum; Chronic Disease; Clo | 1998 |
Flumazenil and hepatic encephalopathy.
Topics: Benzodiazepines; Flumazenil; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoh | 1999 |
The effect of flumazenil on visual event-related potentials of clinically non-encephalopathic patients with cirrhosis.
Topics: Adult; Evoked Potentials, Auditory; Evoked Potentials, Visual; Female; Flumazenil; GABA Modulators; | 1999 |
Hepatic Encephalopathy.
Topics: Adult; Bromocriptine; Dietary Proteins; Digestive System; Flumazenil; Gastrointestinal Agents; Goals | 2001 |
[Chronic liver diseases. The nihilism has gone].
Topics: Amantadine; Antioxidants; Antiviral Agents; Chronic Disease; Dipeptides; Drug Therapy, Combination; | 2001 |
Benzodiazepine antagonist in the treatment of human hepatic encephalopathy.
Topics: Benzodiazepines; Coma; Evoked Potentials, Somatosensory; Flumazenil; Hepatic Encephalopathy; Humans; | 1990 |
[Evaluation of the therapeutic effect of flumazenil in hepatic encephalopathy using cerebral cartography].
Topics: Acute Disease; Aged; Brain Mapping; Chronic Disease; Drug Evaluation; Female; Flumazenil; Hepatic En | 1989 |
[Chronic hepatitis C virus infection and associated liver disease among the inmates of a Spanish prison].
Topics: Adult; Arabs; Biopsy; Comorbidity; Europe; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV | 2009 |